go-v.orgdoi

Emerging therapies in the management of hypertensive patients with osteoarthritis

Giorgio Gentile, Fabio Angeli, Giovanni Mazzotta, Gianpaolo Reboldi, Paolo Verdecchia · Clinical Investigation · 2011

  • DOI 10.4155/cli.10.8
  • Publisher OMICS Publishing Group
  • Type article
  • Issued 2011

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Clinical Investigation · OMICS Publishing Group · article · 2011

Abstract

Osteoarthritis (OA) constitutes one of the leading causes of pain and disability worldwide. The incidence of OA will likely rise over the next few decades, with a significant impact on healthcare costs. Patients with OA are often affected by a number of cardiovascular comorbidities, including hypertension, which is present in approximately 40% of cases. Cyclooxygenase (COX) inhibitors, both nonselective and selective COX-2 inhibitors, are often used to control pain in these patients. Unfortunately, such drugs may cause a variable degree of blood pressure increase.

Because even small increases in blood pressure values may lead to a significant increase in the risk of major cardiovascular events and death, the consequent healthcare concerns have led to the development of the COX-inhibiting nitric oxide donator class of drugs. These new drugs are aimed to improve cardiovascular and gastrointestinal safety profiles, as compared with nonsteroidal anti-inflammatory drugs, through the release of nitric oxide.

Open the resolved locator · 10.4155/cli.10.8

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 23:48 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.4155/cli.10.8
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.